Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child

Addiction

Volumn 111, Issue 12, 2016, Pages 2115-2128

  Zedler, Barbara K ^a   Mann, Ashley L ^a   Kim, Mimi M ^b   Amick, Halle R ^a   Joyce, Andrew R ^a   Murrelle, E Lenn ^a   Jones, Hendrée E ^c,d  

^a Venebio Group LLC   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; dependence; fetus; harm; methadone; opioid use disorder; pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

BIRTH WEIGHT; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INDUCED MALFORMATION; FEMALE; FETUS DEATH; FETUS DEVELOPMENT; HUMAN; META ANALYSIS; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT SAFETY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURITY; PRENATAL CARE; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUDDEN INFANT DEATH SYNDROME;

ABNORMALITIES, DRUG-INDUCED; ANALGESICS, OPIOID; BIRTH WEIGHT; BUPRENORPHINE; FEMALE; FETAL DEATH; FETAL DEVELOPMENT; HUMANS; INFANT, NEWBORN; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT SAFETY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; PRENATAL CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUDDEN INFANT DEATH;

EID: 84978932704     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13462     Document Type: Review

References (71)

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: SAMHSA, 2011 Contract No.: HHS Publication no. (SMA) 11–4658.
2. Maeda A., Bateman B. T., Clancy C. R., Creanga A. A., Leffert L. R. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 2014; 121: 1158–65.
3. Gyarmathy V. A., Giraudon I., Hedrich D., Montanari L., Guarita B., Wiessing L. Drug use and pregnancy—challenges for public health. Euro Surveill 2009; 14: 33–36.
4. De Leon G., Jainchill N. Residential therapeutic communities for female substance abusers. Bull NY Acad Med 1991; 67: 277–90.
5. World Health Organization (WHO). Guidelines for identification and management of substance use and substance use disorders in pregnancy 2014. Available at: http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/ (accessed 1 September 2015) (Archived by WebCite® at http://www.webcitation.org/6gOmIM2FB).
6. Zuspan F., Gumpel J., Mejia-Zelaya A., Madden J., Davis R. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975; 122: 42–6.
7. Dashe J. S., Jackson G. L., Olscher D. A., Zane E. H., Wendel G. D. Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92: 854–8.
8. Luty J., Nikolaou V., Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003; 24: 363–7.
9. Young J. L., Martin P. R. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012; 35: 441–60.
10. American College of Obstetrics and Gynecology The American College of Obstetrics and Gynecology (ACOG) Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119: 1070–76.
11. Jones H. E., Finnegan L. P., Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012; 72: 747–57.
12. Metz V., Köchl B., Fischer G. Should pregnant women with substance use disorders be managed differently? Neuropsychiatry 2012; 2: 29–41.
13. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008; 103: 1429–40.
14. Winklbaur-Hausknost B., Jagsch R., Graf-Rohrmeister K., Unger A., Baewert A., Langer M., et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Hum Psychopharmacol 2013; 28: 15–24.
15. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25: 139–51.
16. World Health Organization (WHO). Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: WHO; 2009.
17. Joseph H., Stancliff S., Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000; 67: 347–64.
18. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82: 250–57.
19. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320–31.
20. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275–81.
21. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1–10.
22. Minozzi S., Amato L., Bellisario C., Ferri M., Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013; 12: CD006318.
23. Liberati A., Altman D. G., Tetzlaff J., Mulrow C., Gotzsche P. C., Ioannidis J. P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med 2009; 6e1000100.
24. Viswanathan M., Ansari M. T., Berkman N. D., Chang S., Hartling L., McPheeters M., Santaguida P. L., et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions; Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. March 2012. AHRQ Publication No. 12-EHC047-EF. Available at: www.effectivehealthcare.ahrq.gov/
25. Guyatt G., Busse J. Methods Commentary: Risk of Bias in Cohort Studies: Evidence Partners; 2015. Available at: https://distillercer.com/resources/methodological-resources/risk-of-bias-in-cohort-studies/ (accessed 10 September 2015) (Archived at http://www.webcitation.org/6gOpc4uqj on 1 September 2015).
26. Wells G., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 1 September 2015) (Archived at http://www.webcitation.org/6gOpODPiP).
27. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.
28. Higgins J. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Oxford, UK: The Cochrane Collaboration; 2011. Available at: http://handbook.cochrane.org/ (accessed 1 September 2015).
29. Welsh A. W. Randomised controlled trials and clinical maternity care: moving on from intention-to-treat and other simplistic analyses of efficacy. BMC Pregnancy Childbirth 2013; 13: 15.
30. Guyatt G. H., Oxman A. D., Kunz R., Woodcock J., Brozek J., Helfand M., et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 2011; 64: 1294–302.
31. West S., Gartlehner G., Mansfield A., Poole C., Tant E., Lenfestey N. et al. Comparative Effectiveness Review Methods: Clinical Heterogeneity. Methods Research Paper (AHRQ Publication No 10-EHC070-EF) (internet). 2010. Available at: http://effectivehealthcare.ahrq.gov/ (accessed 1 September 2015) (Archived at http://www.webcitation.org/6gOoAtvlc).
32. Sterne J. A., Egger M., Smith G. D. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101–5.
33. Berkman N. D., Lohr K. N., Ansari M., McDonagh M., Balk E., Whitlock E. et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update Methods Guide for Comparative Effectiveness Reviews (internet). 2013; AHRQ Publication No. 13(14)-EHC130-EF. Available at: http://effectivehealthcare.ahrq.gov/ehc/products/457/1752/methods-guidance-grading-evidence-131118.pdf (accessed 1 September 2015) (Archived at http://www.webcitation.org/6gOn0I4Tx).
34. Basselin C., Boucher A., Carlier P., Marie-Noelle B., Vial T., Descotes J. Follow-up of pregnancies exposed to buprenorphine maintenance treatment. Fundam Clin Pharmacol 2011; 25: 87.
35. Binder T., Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008; 29: 80–6.
36. Brulet C., Chanal C., Ravel P., Mazurier E., Boulot P., Faucherre V. Multidisciplinary monitoring and psychosocial support reduce complications of opiate dependence in pregnant women: 114 pregnancies. Presse Med 2007; 36: 1571–80.
37. Colombini N., Elias R., Busuttil M., Dubuc M., Einaudi M. A., Bues-Charbit M. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci 2008; 30: 227–34.
38. Gordon A. L., Lopatko O. V., Stacey H., Pearson V., Woods A., Fisk A., et al. Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. J Addict Med 2012; 6: 258–64.
39. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96: 69–78.
40. Konijnenberg C., Melinder A. Visual selective attention is impaired in children prenatally exposed to opioid agonist medication. Eur Addict Res 2014; 21: 63–70.
41. Lacroix I., Berrebi A., Garipuy D., Schmitt L., Hammou Y., Chaumerliac C., et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011; 67: 1053–59.
42. Metz V., Jagsch R., Ebner N., Würzl J., Pribasnig A., Aschauer C., et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol Clin Exp 2011; 26: 412–21.
43. Meyer M. C., Johnston A. M., Crocker A. M., Heil S. H. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med 2015; 9: 81–6.
44. Prasad M., Calaway B., Abdel-Rasoul M. Obstetric and neonatal sequelae of buprenorphine/naloxone (B/N) exposure versus methadone maintenance (MM). Am J Obstet Gynecol 2013; 208: S201.
45. Rohrmeister K., Bernert G., Langer M., Fischer G., Weninger M., Pollak A. Opiate addiction in gravidity—consequences for the newborn. Results of an interdisciplinary treatment concept. Z Geburtshilfe Neonatol 2001; 205: 224–30.
46. Sandtorv L., Reigstad H., Bruaroy S., Elgen I., Laegreid L. M. Substitution treatment of drug addicts during pregnancy: consequences for the children? Tidsskr Nor Laegeforen 2009; 129: 287–90.
47. Siedentopf J. P., Nagel M., Esser M., Casteleyn S., Dudenhausen J. W. Experience with buprenorphine induction and subsequent dose reduction as compared to treatment with L-methadone in pregnant opiate addicts. Geburtshilfe Frauenheilkd 2004; 64: 711–18.
48. Welle-Strand G. K., Skurtveit S., Jones H. E., Waal H., Bakstad B., Bjarko L., et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend 2013; 127: 200–6.
49. Whitham J. N., Spurrier N. J., Sawyer M. G., Baghurst P. A., Taplin J. E., White J. M., et al. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010; 32: 280–8.
50. Jansson L. M., Dipietro J. A., Velez M., Elko A., Williams E., Milio L., et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011; 33: 240–3.
51. Salisbury A. L., Coyle M. G., O'Grady K. E., Heil S. H., Martin P. R., Stine S. M., et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012; 107: 36–44.
52. Holbrook A. M., Baxter J. K., Jones H. E., Heil S. H., Coyle M. G., Martin P. R., et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction 2012; 107: 83–90.
53. Larance B., Lintzeris N., Ali R., Dietze P., Mattick R., Jenkinson R., et al. The diversion and injection of a buprenorphine–naloxone soluble film formulation. Drug Alcohol Depend 2014; 136: 21–7.
54. Martin J. Pregnancy and Buprenorphine Treatment. Providers' Clinical Support System for Medication Assisted Treatment 2014. Available at: http://pcssmat.org/opioid-resources/clinical-tools/ (accessed 27 March 2016) (Archived at http://www.webcitation.org/6gQTmOQHT).
55. DiPietro J. A., Hodgson D. M., Costigan K. A., Hilton S. C., Johnson T. R. Fetal neurobehavioral development. Child Dev 1996; 67: 2553–67.
56. Farquharson R., Exalto N. Early pregnancy—models of healthcare. In: Farquharson R., Stephenson M., editors. Early Pregnancy. New York: Cambridge University Press; 2010. pp. 1-8.
57. Cousens S., Blencowe H., Stanton C., Chou D., Ahmed S., Steinhardt L., et al. National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet 2011; 377: 1319–30.
58. Kandall S. R., Albin S., Gartner L. M., Lee K. S., Eidelman A., Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1: 159–69.
59. Boer K. Substance use in pregnancy: do we care? Acta Paediatr 1994; 83: 65–71.
60. Atik R., Hepworth-Jones B., Doyle P. Risk factors for miscarriage. In: Farquharson R., Stephenson M., editors. Early Pregnancy. New York: Cambridge University Press; 2010. pp. 9-18
61. Maconochie N., Doyle P., Prior S., Simmons R. Risk factors for first trimester miscarriage—results from a UK-population-based case–control study. Br J Obstet Gynaecol 2007; 114: 170–86.
62. Reeves S., Bernstein I. Effects of maternal tobacco-smoke exposure on fetal growth and neonatal size. Exp Rev Obstet Gynecol 2008; 3: 719–30.
63. Olsen I. E., Groveman S. A., Lawson M. L., Clark R. H., Zemel B. S. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214–24.
64. Konijnenberg C., Melinder A. Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. Child Neuropsychol 2011; 17: 495–519.
65. Wittman B., Segal S. A comparison of the effects of the single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991; 26: 213–8.
66. Anchersen K., Clausen T., Gossop M., Hansteen V., Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104: 993–9.
67. Hanon S., Seewald R. M., Yang F., Schweitzer P., Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 2010; 28: 19–22.
68. Ioannidis J. P., Evans S. J., Gotzsche P. C., O'Neill R. T., Altman D. G., Schulz K., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781–8.
69. Chou R., Aronson N., Atkins D., Ismaila A. S., Santaguida P., Smith D. H., et al. AHRQ Series Paper 4: Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. J Clin Epidemiol 2010; 63: 502–12.
70. Egger M., Schneider M., Davey S. G. Spurious precision? Meta-analysis of observational studies. BMJ 1998; 316: 140–4.
71. Norris S. L., Atkins D., Bruening W., Fox S., Johnson E., Kane R., et al. Observational studies in systematic [corrected] reviews of comparative effectiveness: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011; 64: 1178–86.